Natera
ISIN US6323071042
|WKN A14VPJ
Market cap (in EUR)
18,223.26 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.
Healthcare Healthcare Equipment United States
Financials
Key metrics
| Market capitalisation, EUR | 18,223.26 m |
| EPS, EUR | -1.41 |
| P/B ratio | 16.98 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 1,568.75 m |
| Net income, EUR | -176.04 m |
| Profit margin | -11.22% |
What ETF is Natera in?
There are 61 ETFs which contain Natera. All of these ETFs are listed in the table below. The ETF with the largest weighting of Natera is the Global X Genomics & Biotechnology UCITS ETF.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
